Polyamine

Aminex Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer by targeting polyamine metabolism. The company's core strategy, Polyamine Depletion Therapy, aims to starve cancer cells of essential polyamines while simultaneously remodeling the tumor microenvironment to activate the innate immune system. Its lead program, AMXT 1501 in combination with difluoromethylornithine (DFMO), is currently being evaluated in Phase 1b/2 clinical trials for various solid tumors, including breast cancer and melanoma. Aminex also collaborates with pediatric oncology groups to address rare and difficult-to-treat childhood cancers like neuroblastoma.